John E. Friend II
CIK: 0001704021
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KZIA
KAZIA THERAPEUTICS LTD
Officer
Discretionary Trading P&L
Holdings
About Friend John E. II
Friend John E. II (SEC CIK 0001704021) files insider reports with the SEC as Chief Executive Officer of KAZIA THERAPEUTICS LTD (KZIA).
Signal8 holds 3 ownership filings by Friend John E. II (2 Form 3, 1 Form 4), filed between Mar 18, 2026 and Jul 8, 2026. Those filings report 2 transactions, the latest on Jan 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Friend John E. II's filings is in SYDNEY, NSW.
Recent filings by Friend John E. II
- Jan 8, 2026: Grants or awards of KZIA derivative securities (2 lines, Form 4, code A).
Other insiders filing for KAZIA THERAPEUTICS LTD (KZIA)
- Coffey Steven R. S., Director
- Bonacorda Jeffrey, VP, Finance and Controller
- Davidson Ebru, Director
- Cain David, Director, CMC
- APPLE ROBERT F, Director
- Levine James E., Chief Financial Officer